Comments
Biocon has introduced a novel therapy CIMIVIR-L for the treatment of Hepatitis C patients in India.
CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of the product commercialised by Gilead Sciences in the US.
Further, CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV). It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities.
Ravi Limaye, President - Marketing, Biocon, said: "The introduction of CIMIVIR-LTM will strengthen Biocon’s current portfolio of virology products."
The Drugs Controller General of India (DCGI) has recently approved the sale of Sofosbuvir-Ledipasvir combination, which is being manufactured in India under a licence from Gilead.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.